P450-dependent enzymes as targets for prostate cancer therapy

@article{Coster1996P450dependent,
  title={
 P450-dependent enzymes as targets for prostate cancer therapy},
  author={Roland de Coster and Walter Wouters and Jean P Bruynseels},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={1996},
  volume={56},
  pages={133-143}
}
Metastatic prostate adenocarcinoma is a leading cause of cancer-related deaths among men. First line treatment is primarily aimed at blocking the synthesis and action of androgens. As primary endocrine treatment, androgen deprivation is usually achieved by orchidectomy or LHRH analogues, frequently combined with androgen receptor antagonists in order to block the residual adrenal androgens. However, nearly all the patients will eventually relapse. Available or potential second line therapies… Expand
Inhibition of CYP 17, a New Strategy for the Treatment of Prostate Cancer
TLDR
An overview of the current situation in this novel field of drug research and focuses on the development of steroidal and non‐steroidal inhibitors of CYP 17, which catalyzes the last step of androgen biosynthesis in both testes and adrenals. Expand
CYP17 inhibition as a hormonal strategy for prostate cancer
TLDR
A novel, selective, irreversible inhibitor of CYP17 called abiraterone acetate, which is more than 20 times more potent than ketoconazole, is designed and is rapidly progressing from phase II to phase III trials, in view of its high level of antitumor activity. Expand
Targeting CYP17: established and novel approaches in prostate cancer.
TLDR
This review will discuss the rationale for and implications of targeting CYP17 in CRPC and focus on established and novel CYP 17 inhibitors, including ketoconazole, abiraterone acetate, and VN/124-1, which are agents currently at different stages of development. Expand
New agents and strategies for the hormonal treatment of castration-resistant prostate cancer
  • N. Sharifi
  • Biology, Medicine
  • Expert opinion on investigational drugs
  • 2010
TLDR
New investigational hormonal agents that inhibit intratumoral androgens are highly active in the treatment of CRPC, and alternative strategies hold the promise for the development of other agents with novel mechanisms of action. Expand
New cancer drugs targeting the biosynthesis of estrogens and androgens
TLDR
The role of five enzymes involved in the synthesis of steroids and their inhibitors are summarized with a special highlight about the molecules more recently reported in the literature and exhibiting dual therapeutic action. Expand
Changing paradigms in management of metastatic Castration Resistant Prostate Cancer (mCRPC)
TLDR
The rationale for the newly approved hormonal treatments, their indications and complications, and the ongoing trials that are being done to improve the efficacy of the approved agents are presented. Expand
Cellular and molecular signatures of androgen ablation of prostate cancer
TLDR
This chapter discusses how diminished androgen receptor (AR) signaling represents the pivotal mediator of a tightly coordinated signaling response that manifests in loss of AR expression, growth arrest, neuroendocrine differentiation (NED), and survival. Expand
The hurdle of antiandrogen drug resistance: drug design strategies
  • J. Trendel
  • Medicine
  • Expert opinion on drug discovery
  • 2013
TLDR
It is believed that designing compounds that will reduce the activation of the androgen receptor may hold the key to a cure in the future. Expand
Inhibitors of steroidal cytochrome p450 enzymes as targets for drug development.
TLDR
The present article deals with recent patents (focus on publications from 2000 - 2006) concerning P450 inhibitor design where steroidal substrates are involved and a special focus is provided for CYP17 and CYP19. Expand
Study on Cytochrome P-450 Dependent Retinoic Acid Metabolism and its Inhibitors as Potential Agents for Cancer Therapy
TLDR
A wide range of established P-450 inhibitors has been screened to examine their inhibitory activity on all-trans-Retinoic acid (ATRA) metabolism and results indicate that mostly azoles with substituents in positions other than the 1-position on the ring are very weak inhibitors of RA metabolism. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 89 REFERENCES
Inhibitors of P450-dependent steroid biosynthesis: From research to medical treatment
  • H. Bossche
  • Chemistry
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 1992
A number of cytochrome P450-dependent enzymes are major targets for both steroidal and nonsteroidal compounds that may be of use in the treatment of a number of androgen-independent, androgen-,Expand
Current perspectives on aromatase inhibitors in breast cancer.
  • P. Goss, K. Gwyn
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1994
TLDR
From preliminary clinical trials, a new generation of specific and selective aromatase inhibitors appear to have excellent pharmacokinetic profiles and produce few side effects when administered orally, and the future application of these inhibitors in the management of breast cancer remains to be defined. Expand
Ketoconazole: From an antimycotic to a drug for prostate cancer
TLDR
By administering 400 mg ketoconazole orally, every 8 hr, serum testosterone levels in or close to the castrate range were obtained within 1 day in prostate cancer patients, and the adrenal androgens androstenedione and dihydroepiandrosterone were dramatically reduced. Expand
Pharmacology of novel steroidal inhibitors of cytochrome P45017α (17α-hydroxylase/C17–20 lyase)
TLDR
Results indicate that CB7598, CB7630 or CB7627 may be useful in the treatment of hormone-dependent prostatic cancers and no inhibition of corticosterone production by these steroidal compounds is indicated. Expand
Antagonism of androgen action in prostate tumor cells by retinoic acid
TLDR
The data suggest that the suppression of proliferation and function of prostatic cells by RA may be via modulatory effects on the AR, androgen induction of PSA glyco‐protein was also repressed by RA, with maximal inhibition occuring at 10−5 M. Expand
Stimulatory Effects of Androgens, Estrogens, Progestins, and Dexamethasone on the Growth of the LNCaP Human Prostate Cancer Cells
Despite the major medical problems caused by cancer of the prostate, there is a very limited availability of cell lines of human prostatic origin that can be used as models for both in vivo and inExpand
Endocrine effects of high-dose ketoconazole therapy in advanced prostatic cancer.
TLDR
It is concluded that long-term suppression of androgen production can be realized by high-dose ketoconazole treatment and that the degree of suppression is proportional to the serum levels of the drug. Expand
Ketoconazole therapy in advanced prostatic cancer.
TLDR
Because of the ease of administration, rapidity of action, and decrease of adrenal and testicular androgen levels, as well as the relative lack of side effects, ketoconazole may prove to be an important new drug in the treatment of prostatic cancer. Expand
R75251 in Prostate Cancer Patients in Progression after First-Line Hormonal Treatment
TLDR
It is suggested that R75251 has a moderate but definite activity in patients with hormone-refractory prostate cancer and that the value of this drug as second-line treatment in these patients should be further investigated. Expand
Aromatase inhibition in advanced prostatic cancer: preliminary communication.
TLDR
The mechanism of action of 4-OHA in palliating patients with advanced prostatic cancer is obscure at present, but may represent an important new treatment modality which may lead to greater insight into prostatic biology. Expand
...
1
2
3
4
5
...